Abstract
Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.
Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.
Method: Systemic compilation of the relevant literature.
Results & Conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.
Keywords: Biologic agent, chemotherapy, glioblastoma multiforme, immunotherapy, radiation therapy, vaccination.
Current Medicinal Chemistry
Title:Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review
Volume: 24 Issue: 27
Author(s): Ron Batash , Noam Asna *, Pamela Schaffer, Nicole Francis and Moshe Schaffer
Affiliation:
- Barzilai Medical Center, Department of Oncology, Ashkelon,Israel
Keywords: Biologic agent, chemotherapy, glioblastoma multiforme, immunotherapy, radiation therapy, vaccination.
Abstract: Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.
Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.
Method: Systemic compilation of the relevant literature.
Results & Conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.
Export Options
About this article
Cite this article as:
Batash Ron , Asna Noam*, Schaffer Pamela, Francis Nicole and Schaffer Moshe , Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review, Current Medicinal Chemistry 2017; 24 (27) . https://dx.doi.org/10.2174/0929867324666170516123206
DOI https://dx.doi.org/10.2174/0929867324666170516123206 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets The Delicate Equilibrium between Oxidants and Antioxidants in Brain Glioma
Current Neuropharmacology Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Sublethal Total Body Irradiation Leads to Early Cerebellar Damage and Oxidative Stress
Current Neurovascular Research Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery HLA-I Antigen Presentation and Tapasin Influence Immune Responses Against Malignant Brain Tumors-Considerations for Successful Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Meet the Editorial Board:
Current Alzheimer Research Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Current Molecular Medicine Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) PREFACE
Anti-Cancer Agents in Medicinal Chemistry A Nanostructured Silica-Lipid Hybrid to Facilitate Oral SN-38-based Chemotherapy
Drug Delivery Letters Anticancer Active Heterocyclic Chalcones: Recent Developments
Anti-Cancer Agents in Medicinal Chemistry The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Graphene Family of Nanomaterials: Reviewing Advanced Applications in Drug delivery and Medicine
Current Drug Delivery Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Non-Steroidal Anti-Inflammatory Drugs used as a Treatment Modality in Subarachnoid Hemorrhage
Current Drug Safety Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design